{"DataElement":{"publicId":"7125041","version":"1","preferredName":"Tumor Segment Percent Stromal Cell Nuclei Integer","preferredDefinition":"An integer number between 0 and 100 to capture the percent of stromal cell nuclei in a sample compared to the total number of nuclei in the sample.","longName":"7120643v1.0:6847952v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7120643","version":"1","preferredName":"Tumor Segment Percent Stromal Cell Nuclei","preferredDefinition":"Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis._A quantitative measurement of the percent of stromal cell nuclei in a sample compared to the total number of nuclei in the sample.","longName":"7119487v1.0:7120641v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"7119487","version":"1","preferredName":"Tumor Segment","preferredDefinition":"Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis.","longName":"C162622","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Segment","conceptCode":"C162622","definition":"Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B7C823A-3A71-01FE-E053-F662850AC3D6","latestVersionIndicator":"Yes","beginDate":"2020-01-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-06","modifiedBy":"ONEDATA","dateModified":"2020-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7120641","version":"1","preferredName":"Percent Stromal Cell Nuclei","preferredDefinition":"A quantitative measurement of the percent of stromal cell nuclei in a sample compared to the total number of nuclei in the sample.","longName":"C165617","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percent Stromal Cell Nuclei","conceptCode":"C165617","definition":"A quantitative measurement of the percent of stromal cell nuclei in a sample compared to the total number of nuclei in the sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B7D2028-3BCF-25B5-E053-F662850AB887","latestVersionIndicator":"Yes","beginDate":"2020-01-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-06","modifiedBy":"ONEDATA","dateModified":"2020-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435029","version":"1","preferredName":"Molecular Abnormality","preferredDefinition":"Abnormalities that occur in human cells and tissues and models of human cancer.","longName":"C3910","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07432BB3-787B-25DB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9B7D2028-3BE0-25B5-E053-F662850AB887","latestVersionIndicator":"Yes","beginDate":"2020-01-06","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-06","modifiedBy":"KNABLEJ","dateModified":"2020-02-13","changeDescription":"1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/6/20 jk created for CPTAC Path Review CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6847952","version":"1","preferredName":"Integer","preferredDefinition":"A positive number with no fractional part between 0 and 100.","longName":"6847952v1.0","context":"OCCPR","contextVersion":"1","type":"Non-enumerated","dataType":"Integer","minLength":"1","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433737","version":"1","preferredName":"Integer","preferredDefinition":"A number with no fractional part.","longName":"C45255","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4769-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-25","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-25","modifiedBy":"ONEDATA","dateModified":"2005-11-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F867DFE-8763-5C6C-E053-F662850A9F8B","latestVersionIndicator":"Yes","beginDate":"2019-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-08-07","modifiedBy":"KNABLEJ","dateModified":"2020-01-22","changeDescription":"1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set.  8/7/19 jk created for CPTAC baseline CRFs.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"7218867","version":"1","longName":"Head and Neck","context":"OCCPR"},{"publicId":"6601275","version":"1","longName":"Brain","context":"OCCPR"},{"publicId":"6779546","version":"1","longName":"LGG Pathology Review","context":"OCCPR"},{"publicId":"5635361","version":"1","longName":"Bladder","context":"OCCPR"},{"publicId":"6779608","version":"1","longName":"BLCA Pathology Review","context":"OCCPR"},{"publicId":"10000439","version":"1","longName":"Thyroid","context":"OCCPR"},{"publicId":"6779573","version":"1","longName":"THCA Pathology Review","context":"OCCPR"},{"publicId":"6776735","version":"1","longName":"Eye","context":"OCCPR"},{"publicId":"6779576","version":"1","longName":"UVM Pathology Review","context":"OCCPR"},{"publicId":"6570063","version":"1","longName":"Cervix","context":"OCCPR"},{"publicId":"6779611","version":"1","longName":"CESC Pathology Review","context":"OCCPR"},{"publicId":"6776762","version":"1","longName":"Bile duct and Liver","context":"OCCPR"},{"publicId":"6779540","version":"1","longName":"CHOL Pathology Review","context":"OCCPR"},{"publicId":"6779543","version":"1","longName":"LIHC Pathology Review","context":"OCCPR"},{"publicId":"6601282","version":"1","longName":"Esophagus","context":"OCCPR"},{"publicId":"6779555","version":"1","longName":"ESCA Pathology Review","context":"OCCPR"},{"publicId":"5635376","version":"1","longName":"Prostate","context":"OCCPR"},{"publicId":"6779563","version":"1","longName":"PRAD Pathology Review","context":"OCCPR"},{"publicId":"6570064","version":"1","longName":"Stomach","context":"OCCPR"},{"publicId":"6779568","version":"1","longName":"STAD Pathology Review","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Percent stromal cell nuclei","type":"Preferred Question Text","description":"Percent stromal cell nuclei","url":null,"context":"OCCPR"},{"name":"CPTAC-1","type":"Coding Instructions","description":"The assessment of percent stromal nuclei should include only stromal cells.  It is the proportion of stromal cell nuclei (numerator) as compared to all cell nuclei (denominator) across the entire section.  Note, the nuclei of tumor stroma, inflammatory cells within the region of tumor, etc. are to be included in the denominator.","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9BA1A37F-8D65-592E-E053-F662850AE350","latestVersionIndicator":"Yes","beginDate":"2020-01-08","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-01-08","modifiedBy":"ONEDATA","dateModified":"2022-09-08","changeDescription":"7/12/21 jk added HNSCC Path Rpt CSI. 5/7/20 jk added LGG CSI. 1/29/20 jk added coding instruction from Linda.  1/22/20 jk released per CPTAC SME's review of PRAD Path Review CDE set. 1/8/20 jk created for CPTAC Path Review CRFs; applicable to all tumor types.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}